Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

During median follow-up of 5·4 years, renal outcome (first occurrence of new macroalbuminuria, sustained decline in eGFR of >30%, or chronic renal replacement therapy) occurred in 17.1% of dulaglutide group vs 19.6% of placebo group (HR 0.85; p=0.0004).

The authors of a related commentary note that the REWIND trials add to the growing body of evidence that GLP-1 receptor agonists afford cardiovascular superiority, even in primary prevention, in terms of preventing atherosclerotic events, and potentially affording renal protection.

The original REWIND study (n=9901) reported that dulaglutide significantly reduced composite CVD endpoint vs placebo (12% vs 13.4%; HR 0.88; p=0.026).